Journal of hepatology · 2026
Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL).
СтатьяКлиническое исследование II фазыНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bhoori Sherrie, Rivoltini Licia, Pinato David J, Bellia Valentina, Maspero Marianna, Bongini Marco, de Cristofaro Jacopo, Vaiani Marta, Dosi Michela, Vergani Elisabetta, Vergani Barbara, Leoncini Giuseppe, Daveri Elena, Di Maio Giovanni, Simonotti Nicolò, Cappetti Barbara, Cova Agata, Rini Francesca, Bergamini Stefano, Lalli Luca, Sposito Carlo, Mazzaferro Vincenzo
Аннотация
BACKGROUND & AIMS: Liver transplantation (LT) is a curative treatment option in early and intermediate hepatocellular carcinoma (HCC) following downstaging with locoregional therapies (LRT). Tumor response to immune checkpoint inhibitors may extend LT eligibility to intermediate and advanced stages.
METHODS: In this prospective phase II study, patients with intermediate and advanced HCCs beyond extended transplant criteria, not amenable to further LRTs, were downstaged with atezolizumab-bevacizumab (Atezo-Bev) prior to LT. The primary endpoint was recurrence-free survival with safety and efficacy as additional outcomes. Spectral quantitative pathology and immune signatures in tumor tissue and peripheral blood were studied longitudinally.
RESULTS: Sixteen patients with HCC beyond expanded transplant criteria (median tumor size 6.5 cm [IQR 3-8], median AFP 283 ng/ml [IQR 6-1,080], portal vein thrombosis 50%) were downstaged to LT after a median of 4.7 months (IQR 2.4-7.6). Prior LRTs were used in 15 (94%) patients. The washout period from the last Atezo-Bev dose to transplant was 57.5 (IQR 29-87) days. Median follow-up was 16 months (95% CI 4-22). Pre-transplant immune-related adverse events occurred in 3 (19%) patients and post-transplant acute rejection in 4 (25%). Post-LT 90-day morbidity and mortality were 62.5% (95% CI 35-85%) and 6.3% (95% CI 0.2-30%) respectively. Explant pathology revealed 10 complete and 6 partial responses. Responding patients harboured a tumor microenvironment with features suggestive of immune activation/extinguishment, correlated with duration of Atezo-Bev treatment and length of pre-LT washout. One (6.2%) HCC post-LT recurrence occurred during follow-up. Recurrence-free and post-transplant overall survival were 90% and 94% after 2 years, respectively.
CONCLUSIONS: LT following Atezo-Bev downstaging achieves promising recurrence-free survival in intermediate and advanced HCC beyond conventional transplant criteria. Acute rejection seemed to be increased but was clinically manageable. LT should be considered in patients with HCC who respond to immunotherapy.
IMPACT AND IMPLICATIONS: Immune checkpoint inhibitors are now standard treatment for advanced hepatocellular carcinoma (HCC) and some intermediate-stage cases. Emerging evidence suggests that immunotherapy may also have a role in the neoadjuvant setting before liver resection or transplantation. By inducing tumor responses, immunotherapy may downstage patients initially ineligible for curative therapies, enabling liver transplantation (LT) and favorable post-transplant outcomes. However, treatment-related adverse events, particularly graft rejection, must be balanced against potential survival benefits. In this first prospective study evaluating LT after atezolizumab-bevacizumab (Atezo-Bev) in patients with intermediate or advanced HCC not amenable to other therapies, 26% achieved transplant eligibility. Two-year post-LT outcomes were comparable to those observed with conventional transplant criteria. Immune monitoring indicated that tumor response and graft rejection are closely linked through the PD-1/PD-L1 pathway. Although rejection risk appeared increased, it was manageable with standard steroids and intensified early immunosuppression. These findings support considering expanded transplant criteria in selected patients with sustained responses to immunotherapy.
REGISTRATION NUMBER: NCT05879328.
METHODS: In this prospective phase II study, patients with intermediate and advanced HCCs beyond extended transplant criteria, not amenable to further LRTs, were downstaged with atezolizumab-bevacizumab (Atezo-Bev) prior to LT. The primary endpoint was recurrence-free survival with safety and efficacy as additional outcomes. Spectral quantitative pathology and immune signatures in tumor tissue and peripheral blood were studied longitudinally.
RESULTS: Sixteen patients with HCC beyond expanded transplant criteria (median tumor size 6.5 cm [IQR 3-8], median AFP 283 ng/ml [IQR 6-1,080], portal vein thrombosis 50%) were downstaged to LT after a median of 4.7 months (IQR 2.4-7.6). Prior LRTs were used in 15 (94%) patients. The washout period from the last Atezo-Bev dose to transplant was 57.5 (IQR 29-87) days. Median follow-up was 16 months (95% CI 4-22). Pre-transplant immune-related adverse events occurred in 3 (19%) patients and post-transplant acute rejection in 4 (25%). Post-LT 90-day morbidity and mortality were 62.5% (95% CI 35-85%) and 6.3% (95% CI 0.2-30%) respectively. Explant pathology revealed 10 complete and 6 partial responses. Responding patients harboured a tumor microenvironment with features suggestive of immune activation/extinguishment, correlated with duration of Atezo-Bev treatment and length of pre-LT washout. One (6.2%) HCC post-LT recurrence occurred during follow-up. Recurrence-free and post-transplant overall survival were 90% and 94% after 2 years, respectively.
CONCLUSIONS: LT following Atezo-Bev downstaging achieves promising recurrence-free survival in intermediate and advanced HCC beyond conventional transplant criteria. Acute rejection seemed to be increased but was clinically manageable. LT should be considered in patients with HCC who respond to immunotherapy.
IMPACT AND IMPLICATIONS: Immune checkpoint inhibitors are now standard treatment for advanced hepatocellular carcinoma (HCC) and some intermediate-stage cases. Emerging evidence suggests that immunotherapy may also have a role in the neoadjuvant setting before liver resection or transplantation. By inducing tumor responses, immunotherapy may downstage patients initially ineligible for curative therapies, enabling liver transplantation (LT) and favorable post-transplant outcomes. However, treatment-related adverse events, particularly graft rejection, must be balanced against potential survival benefits. In this first prospective study evaluating LT after atezolizumab-bevacizumab (Atezo-Bev) in patients with intermediate or advanced HCC not amenable to other therapies, 26% achieved transplant eligibility. Two-year post-LT outcomes were comparable to those observed with conventional transplant criteria. Immune monitoring indicated that tumor response and graft rejection are closely linked through the PD-1/PD-L1 pathway. Although rejection risk appeared increased, it was manageable with standard steroids and intensified early immunosuppression. These findings support considering expanded transplant criteria in selected patients with sustained responses to immunotherapy.
REGISTRATION NUMBER: NCT05879328.